Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2009

01.12.2009 | Breast Oncology

Ratio Between Positive Lymph Nodes and Total Excised Axillary Lymph Nodes as an Independent Prognostic Factor for Overall Survival in Patients with Nonmetastatic Lymph Node-Positive Breast Cancer

verfasst von: Hassan A. Hatoum, MD, Faek R. Jamali, MD, Nagi S. El-Saghir, MD, Khaled M. Musallam, MD, Muhieddine Seoud, MD, Hani Dimassi, PhD, Jaber Abbas, MD, Mohamad Khalife, MD, Fouad I. Boulos, MD, Ayman N. Tawil, MD, Fadi B. Geara, MD, Ziad Salem, MD, Achraf A. Shamseddine, BSc, Karine Al-Feghali, BSc, Ali I. Shamseddine, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

The status of the axillary lymph nodes in nonmetastatic lymph node-positive breast cancer (BC) patients remains the single most important determinant of overall survival (OS). Although the absolute number of nodes involved with cancer is important for prognosis, the role of the total number of excised nodes has received less emphasis. Thus, several studies have focused on the utility of the axillary lymph node ratio (ALNR) as an independent prognostic indicator of OS. However, most studies suffered from shortcomings, such as including patients who received neoadjuvant therapy or failing to consider the use of adjuvant therapy and tumor receptor status in their analysis.

Methods

We conducted a single-center retrospective review of 669 patients with nonmetastatic lymph node-positive BC. Data collected included patient demographics; breast cancer risk factors; tumor size, histopathological, receptor, and lymph node status; and treatment modalities used. Patients were subdivided into four groups according to ALNR value (<.25, .25–.49, .50–.74, .75–1.00). Study parameters were compared at the univariate and multivariate levels for their effect on OS.

Results

On univariate analysis, both the absolute number of positive lymph nodes and the ALNR were significant predictors of OS. On multivariate analysis, only the ALNR remained an independent predictor of OS, with a 2.5-fold increased risk of dying at an ALNR of ≥.25.

Conclusions

Our study demonstrates that ALNR is a stronger factor in predicting OS than the absolute number of positive axillary lymph nodes.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.CrossRefPubMed Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.CrossRefPubMed
2.
Zurück zum Zitat Morton DL. Intra-operative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation? Cancer J Sci Am. 1997;3:328–30.PubMed Morton DL. Intra-operative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation? Cancer J Sci Am. 1997;3:328–30.PubMed
3.
Zurück zum Zitat Kutiyanawala MA, Sayed M, Stotter A, et al. Staging the axilla in breast cancer: an audit of lymph-node retrieval in one UK regional centre. Eur J Surg Oncol. 1998;24:280–5.CrossRefPubMed Kutiyanawala MA, Sayed M, Stotter A, et al. Staging the axilla in breast cancer: an audit of lymph-node retrieval in one UK regional centre. Eur J Surg Oncol. 1998;24:280–5.CrossRefPubMed
4.
Zurück zum Zitat Smeets A, Christiaens MR. Implications of the sentinel lymph node procedure for local and systemic adjuvant treatment. Curr Opin Oncol. 2005;17:539–44.CrossRefPubMed Smeets A, Christiaens MR. Implications of the sentinel lymph node procedure for local and systemic adjuvant treatment. Curr Opin Oncol. 2005;17:539–44.CrossRefPubMed
5.
Zurück zum Zitat Schulze T, Mucke J, Markwardt J, et al. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol. 2006;93:109–19.CrossRefPubMed Schulze T, Mucke J, Markwardt J, et al. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol. 2006;93:109–19.CrossRefPubMed
6.
Zurück zum Zitat Woodward WA, Strom EA, Tucker SL, et al. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol. 2003;21:3244–8.CrossRefPubMed Woodward WA, Strom EA, Tucker SL, et al. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol. 2003;21:3244–8.CrossRefPubMed
7.
Zurück zum Zitat Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999;17:1689–700.PubMed Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999;17:1689–700.PubMed
8.
Zurück zum Zitat Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22:4247–54.CrossRefPubMed Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22:4247–54.CrossRefPubMed
9.
Zurück zum Zitat Vinh-Hung V, Burzykowski T, Cserni G, et al. Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. Int J Oncol. 2003;22:697–704.PubMed Vinh-Hung V, Burzykowski T, Cserni G, et al. Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. Int J Oncol. 2003;22:697–704.PubMed
10.
Zurück zum Zitat Vinh-Hung V, Cserni G, Burzykowski T, et al. Effect of the number of uninvolved nodes on survival in early breast cancer. Oncol Rep. 2003;10:363–8.PubMed Vinh-Hung V, Cserni G, Burzykowski T, et al. Effect of the number of uninvolved nodes on survival in early breast cancer. Oncol Rep. 2003;10:363–8.PubMed
11.
Zurück zum Zitat Krag DN, Single RM. Breast cancer survival according to number of nodes removed. Ann Surg Oncol. 2003;10:1152–9.CrossRefPubMed Krag DN, Single RM. Breast cancer survival according to number of nodes removed. Ann Surg Oncol. 2003;10:1152–9.CrossRefPubMed
12.
Zurück zum Zitat van der Wal BC, Butzelaar RM, van der Meij S, et al. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol. 2002;28:481–9.CrossRefPubMed van der Wal BC, Butzelaar RM, van der Meij S, et al. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol. 2002;28:481–9.CrossRefPubMed
13.
Zurück zum Zitat Voordeckers M, Vinh-Hung V, Van de Steene J, et al. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004;70:225–30.CrossRefPubMed Voordeckers M, Vinh-Hung V, Van de Steene J, et al. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004;70:225–30.CrossRefPubMed
14.
Zurück zum Zitat Vinh-Hung V, Verschraegen C, Promish DI, et al. Ratios of involved nodes in early breast cancer. Breast Cancer Res. 2004;6:R680–8.CrossRefPubMed Vinh-Hung V, Verschraegen C, Promish DI, et al. Ratios of involved nodes in early breast cancer. Breast Cancer Res. 2004;6:R680–8.CrossRefPubMed
15.
Zurück zum Zitat Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer. 2005;103:2006–13.CrossRefPubMed Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer. 2005;103:2006–13.CrossRefPubMed
16.
Zurück zum Zitat Kuru B. Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. Eur J Surg Oncol. 2006;32:1082–8.CrossRefPubMed Kuru B. Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. Eur J Surg Oncol. 2006;32:1082–8.CrossRefPubMed
17.
Zurück zum Zitat Lale Atahan I, Yildiz F, Ozyigit G, et al. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer. Acta Oncol. 2008;47:232–8.CrossRefPubMed Lale Atahan I, Yildiz F, Ozyigit G, et al. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer. Acta Oncol. 2008;47:232–8.CrossRefPubMed
18.
Zurück zum Zitat Vinh-Hung V, Verkooijen HM, Fioretta G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27:1062–8.CrossRefPubMed Vinh-Hung V, Verkooijen HM, Fioretta G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27:1062–8.CrossRefPubMed
19.
Zurück zum Zitat Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York, NY: Springer; 2002. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York, NY: Springer; 2002.
20.
Zurück zum Zitat Atkinson EN, Brown BW, Montague ED. Tumor volume, nodal status, and metastasis in breast cancer in women. J Natl Cancer Inst. 1986;76:171–8.PubMed Atkinson EN, Brown BW, Montague ED. Tumor volume, nodal status, and metastasis in breast cancer in women. J Natl Cancer Inst. 1986;76:171–8.PubMed
21.
Zurück zum Zitat Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–7.CrossRefPubMed Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–7.CrossRefPubMed
22.
Zurück zum Zitat Gray RJ. Flexible methods for analyzing survival data using splines, with application to breast cancer prognosis. J Am Stat Assoc. 1992;87:942–51.CrossRef Gray RJ. Flexible methods for analyzing survival data using splines, with application to breast cancer prognosis. J Am Stat Assoc. 1992;87:942–51.CrossRef
23.
Zurück zum Zitat Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998;52:227–37.CrossRefPubMed Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998;52:227–37.CrossRefPubMed
24.
Zurück zum Zitat Sauerbrei W, Royston P, Bojar H, et al. Modelling the effects of standard prognostic factors in nodepositive breast cancer: German Breast Cancer Study Group (GBSG). Br J Cancer. 1999;79:1752–60.CrossRefPubMed Sauerbrei W, Royston P, Bojar H, et al. Modelling the effects of standard prognostic factors in nodepositive breast cancer: German Breast Cancer Study Group (GBSG). Br J Cancer. 1999;79:1752–60.CrossRefPubMed
25.
Zurück zum Zitat McMasters KM. The eternally enigmatic axilla: further controversy about axillary lymph node in breast cancer. Ann Surg Oncol. 2003;10:1128–30.CrossRefPubMed McMasters KM. The eternally enigmatic axilla: further controversy about axillary lymph node in breast cancer. Ann Surg Oncol. 2003;10:1128–30.CrossRefPubMed
26.
Zurück zum Zitat Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–17. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–17.
27.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15- year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15- year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.
28.
Zurück zum Zitat Baslaim MM, Al Malik OA, Al Sobhi SS, et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. Am J Surg. 2002;184:299–301.CrossRefPubMed Baslaim MM, Al Malik OA, Al Sobhi SS, et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. Am J Surg. 2002;184:299–301.CrossRefPubMed
29.
Zurück zum Zitat Kyndi M, Sørensen FB, Knudsen H, et al. Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–26.CrossRefPubMed Kyndi M, Sørensen FB, Knudsen H, et al. Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–26.CrossRefPubMed
30.
Zurück zum Zitat The Steering Committee on Clinical Practice. Guidelines for the care and treatment of breast cancer. CMAJ. 1998;158(Suppl 3):S1–2. The Steering Committee on Clinical Practice. Guidelines for the care and treatment of breast cancer. CMAJ. 1998;158(Suppl 3):S1–2.
31.
Zurück zum Zitat Weir L, Speers C, D’Yachkova Y, et al. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol. 2002;20:1793–9.CrossRefPubMed Weir L, Speers C, D’Yachkova Y, et al. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol. 2002;20:1793–9.CrossRefPubMed
32.
Zurück zum Zitat Fowble B, Solin LJ, Schultz DJ, et al. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys. 1989;17:703–10.PubMed Fowble B, Solin LJ, Schultz DJ, et al. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys. 1989;17:703–10.PubMed
33.
Zurück zum Zitat Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian meta-analysis. Ann Surg Oncol. 1999;6:109–16.CrossRefPubMed Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian meta-analysis. Ann Surg Oncol. 1999;6:109–16.CrossRefPubMed
34.
Zurück zum Zitat Chaudhry R, Goel V, Sawka C. Breast cancer survival by teaching status of the initial treating hospital. CMAJ. 2001;164:183–8.PubMed Chaudhry R, Goel V, Sawka C. Breast cancer survival by teaching status of the initial treating hospital. CMAJ. 2001;164:183–8.PubMed
35.
Zurück zum Zitat Sosa JA, Diener-West M, Gusev Y, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol. 1998;5:140–9.CrossRefPubMed Sosa JA, Diener-West M, Gusev Y, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol. 1998;5:140–9.CrossRefPubMed
36.
Zurück zum Zitat Gillanders WE, Mikhitarian K, Hebert R, et al. Molecular detection of micrometastatic breast cancer in histopathologynegative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg. 2004;239:828–37.CrossRefPubMed Gillanders WE, Mikhitarian K, Hebert R, et al. Molecular detection of micrometastatic breast cancer in histopathologynegative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg. 2004;239:828–37.CrossRefPubMed
37.
Zurück zum Zitat Cserni G, Bianchi S, Boecker W, et al. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer. 2005;103:358–67.CrossRefPubMed Cserni G, Bianchi S, Boecker W, et al. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer. 2005;103:358–67.CrossRefPubMed
38.
Zurück zum Zitat Turner RR, Weaver DL, Cserni G, et al. Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. J Clin Oncol. 2008;26:258–63.CrossRefPubMed Turner RR, Weaver DL, Cserni G, et al. Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. J Clin Oncol. 2008;26:258–63.CrossRefPubMed
39.
Zurück zum Zitat Sakorafas GH, Tsiotou AG, Balsiger BM. Axillary lymph node dissection in breast cancer—current status and controversies, alternative strategies and future perspectives. Acta Oncol. 2000;39:455–66.CrossRefPubMed Sakorafas GH, Tsiotou AG, Balsiger BM. Axillary lymph node dissection in breast cancer—current status and controversies, alternative strategies and future perspectives. Acta Oncol. 2000;39:455–66.CrossRefPubMed
40.
Zurück zum Zitat Bundred NJ, Morgan DA, Dixon JM. ABC of breast diseases. Management of regional nodes in breast cancer. Br Med J. 1994;309:1222–5. Bundred NJ, Morgan DA, Dixon JM. ABC of breast diseases. Management of regional nodes in breast cancer. Br Med J. 1994;309:1222–5.
Metadaten
Titel
Ratio Between Positive Lymph Nodes and Total Excised Axillary Lymph Nodes as an Independent Prognostic Factor for Overall Survival in Patients with Nonmetastatic Lymph Node-Positive Breast Cancer
verfasst von
Hassan A. Hatoum, MD
Faek R. Jamali, MD
Nagi S. El-Saghir, MD
Khaled M. Musallam, MD
Muhieddine Seoud, MD
Hani Dimassi, PhD
Jaber Abbas, MD
Mohamad Khalife, MD
Fouad I. Boulos, MD
Ayman N. Tawil, MD
Fadi B. Geara, MD
Ziad Salem, MD
Achraf A. Shamseddine, BSc
Karine Al-Feghali, BSc
Ali I. Shamseddine, MD
Publikationsdatum
01.12.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0653-8

Weitere Artikel der Ausgabe 12/2009

Annals of Surgical Oncology 12/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.